Fulcrum Therapeutics (FULC) Change in Accured Expenses (2019 - 2026)

Fulcrum Therapeutics (FULC) has disclosed Change in Accured Expenses for 7 consecutive years, with $2.3 million as the latest value for Q4 2025.

  • Quarterly Change in Accured Expenses rose 457.97% to $2.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.0 million through Dec 2025, up 199.32% year-over-year, with the annual reading at $1.0 million for FY2025, 199.32% up from the prior year.
  • Change in Accured Expenses for Q4 2025 was $2.3 million at Fulcrum Therapeutics, up from $1.5 million in the prior quarter.
  • The five-year high for Change in Accured Expenses was $5.8 million in Q2 2022, with the low at -$4.5 million in Q3 2022.
  • Average Change in Accured Expenses over 5 years is $83650.0, with a median of $679000.0 recorded in 2023.
  • Peak annual rise in Change in Accured Expenses hit 2313.0% in 2021, while the deepest fall reached 2115.38% in 2021.
  • Over 5 years, Change in Accured Expenses stood at -$795000.0 in 2021, then soared by 296.48% to $1.6 million in 2022, then crashed by 41.81% to $909000.0 in 2023, then plummeted by 170.41% to -$640000.0 in 2024, then skyrocketed by 457.97% to $2.3 million in 2025.
  • According to Business Quant data, Change in Accured Expenses over the past three periods came in at $2.3 million, $1.5 million, and $587000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.